BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anamorelin: Phase III started

Helsinn began the double-blind, placebo-controlled, international Phase III ROMANA-1 trial to evaluate once-daily 100 mg anamorelin in 477 patients with non-small cell lung cancer (NSCLC). Patients will have the option to continue treatment in the 12-week safety...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >